Dongkook Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

No data to show

P/E

12.39

P/S

0.93

EPS

1,392.75

Div Yield, %

—

Shrs. gr., 5y

0.02%

Rev. gr., 5y

10.99%

Revenues

812.17b

+11.10%

Net income

61.22b

+29.77%

CFO

76.09b

+82.07%

Dividend

Dec 27, 2023180 KRW/sh

Earnings

Aug 12, 2025

Profile

DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durakinase, and Lorelin Depot injections; produces various natural product materials, such as black cohosh extract and magnolia extract comprises ETIZM and TECA; and natural herb medicines. In addition, it provides general and prescription-based drugs; medical devices; ETC and cosmetic products; and quasi drugs that include lipossol hydrocare bandage. DongKook Pharmaceutical Co., Ltd. also exports its products to approximately 40 countries, including Japan, Europe, Central and South America, and India. The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982. DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

URL

http://www.dkpharm.co.kr/

IPO date

May 29, 2007

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	812,166,073 11.10%	730,993,597 10.48%	661,647,492 11.35%
Cost of revenue	645,477,011	590,766,050	517,228,159
Unusual Expense (Income)
NOPBT	166,689,062	140,227,547	144,419,333
NOPBT Margin	20.52%	19.18%	21.83%
Operating Taxes	22,401,495	11,966,256	13,875,730
Tax Rate	13.44%	8.53%	9.61%
NOPAT	144,287,567	128,261,291	130,543,603
Net income	61,218,953 29.77%	47,175,203 -10.82%	52,895,927 5.07%
Dividends	(8,313,066)	(8,050,633)	(8,049,373)
Dividend yield	1.12%	1.11%	1.08%
Proceeds from repurchase of equity		(2,420,863)
BB yield		0.33%
Debt
Debt current	52,059,746	56,485,207	63,933,023
Long-term debt	37,439,388	24,215,521	27,448,968
Deferred revenue	643,829		920,000
Other long-term liabilities	5,720,638	11,989,428	8,000,405
Net debt	(80,434,469)	(121,759,274)	(122,475,634)
Cash flow
Cash from operating activities	76,090,783	41,792,951	49,158,510
CAPEX	(26,567,864)	(34,176,699)	(51,229,874)
Cash from investing activities	(64,864,253)	(52,390,667)	(20,753,121)
Cash from financing activities	(22,304,975)	(2,297,966)	(38,893,322)
FCF	55,962,688	107,203,963	72,781,013
Balance
Cash	90,853,921	94,159,871	107,104,759
Long term investments	79,079,682	108,300,131	106,752,866
Excess cash	129,325,300	165,910,322	180,775,251
Stockholders' equity	656,322,389	561,412,454	519,789,027
Invested Capital	561,203,126	498,956,644	437,850,026
ROIC	27.22%	27.38%	31.92%
ROCE	21.58%	21.09%	23.17%
EV
Common stock shares outstanding	44,772	44,731	44,724
Price	16,520.00 2.23%	16,160.00 -2.65%	16,600.00 -23.85%
Market cap	739,635,687 2.32%	722,851,942 -2.63%	742,414,167 -23.84%
EV	735,085,307	632,957,533	649,448,700
EBITDA	195,151,149	161,325,143	163,595,520
EV/EBITDA	3.77	3.92	3.97
Interest	4,497,460	5,867,708	4,319,783
Interest/NOPBT	2.70%	4.18%	2.99%